CytomX Therapeutics (CTMX) AI Stock Analysis

• Market Cap: $381.26M
• Dividend Yield: N/A
• Average Volume (3M): 2.46M
• Price to Earnings (P/E): 4.8
• Beta (1Y): 3.08
• Revenue Growth: 23.81%
• EPS Growth: 146.45%
• Country: US
• Employees: 119
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.27
• Shares Outstanding: 157,544,370
• 10 Day Avg. Volume: 1,730,960
• 30 Day Avg. Volume: 2,456,091
• PEG Ratio: 0.19
• Price to Book (P/B): 8.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.62
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 0.63
• Enterprise Value/Gross Profit: 2.28
• Enterprise Value/Ebitda: 4.18
• 1Y Price Target: $4.50
• Price Target Upside: 88.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 68 Neutral
• Price Target: $2.50 ▲(4.60%Upside)

CytomX Therapeutics shows strong technical momentum and attractive valuation, driven by positive corporate events such as Nasdaq compliance and interim trial data. While financial instability due to negative equity and cash flow issues is a concern, the company's upward trajectory and strategic funding efforts bolster its outlook.

Positive Factors

Clinical data

CytomX reported highly encouraging clinical data for its masked EpCAM ProBody Topo-1 ADC, CX-2051 in patients with late-line colorectal cancer.

Financial performance

CytomX reported its FY2024 financials, recording a net profit of $0.38 per share for the period vs. prior estimate of net profit of $0.14 per share.

Pipeline development

Cost reductions due to restructuring initiatives and focused pipeline prioritization are expected to extend CytomX's cash runway into 2Q26.

Negative Factors

Clinical trial risks

Risks include, but are not limited to: clinical trial delays and failure to generate favorable clinical data, particularly with CX-2051 in CRC.

Pipeline setbacks

CX-904 discontinuation adds to history of pipeline setbacks.

Pipeline uncertainty

The discontinuation creates another roadblock for CytomX in advancing its PROBODY-based programs through the clinic.

CytomX Therapeutics Business Overview & Revenue Model

Company Description

CytomX Therapeutics (CTMX) is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company specializes in the development of conditionally activated therapeutics, utilizing its proprietary Probody technology platform. This platform aims to improve the therapeutic window of antibodies, reducing off-target toxicity and enhancing the efficacy of cancer treatments. CytomX is headquartered in South San Francisco, California, and is dedicated to creating transformative therapies for patients with difficult-to-treat cancers.

How the Company Makes Money

CytomX Therapeutics makes money primarily through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and potential royalties on future product sales. CytomX collaborates with companies like Bristol-Myers Squibb and AbbVie, leveraging its Probody platform to develop innovative cancer treatments. Additionally, the company may also receive grant funding and research support from various institutions. These revenue streams are crucial for funding their research and development activities, as CytomX is still in the clinical stage and does not yet have products generating direct sales revenue.

CytomX Therapeutics Financial Statement Overview

Summary

CytomX Therapeutics has shown positive revenue growth and improved profitability margins, indicating operational recovery. However, negative equity, potential solvency risks, and cash flow difficulties present significant financial instability.

Income Statement

CytomX Therapeutics showed a positive revenue growth rate from 2023 to 2024, with total revenue increasing from $101.21 million to $138.10 million, representing a growth rate of approximately 36.4%. The gross profit margin remained strong at 100% due to no cost of goods sold. However, the net profit margin improved significantly in 2024, reaching approximately 23.1%, compared to a negative margin in 2023. The EBIT and EBITDA margins also turned positive, indicating improved operational efficiency. Despite these improvements, historical volatility and past losses present a risk.

Balance Sheet

The balance sheet reflects a concerning negative equity position in 2024, with stockholders' equity at -$456,000, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, but total debt decreased over the year. The equity ratio is negative, which poses a significant risk to financial stability. This indicates potential solvency issues despite reducing total debt.

Cash Flow

The cash flow statement shows a deterioration in free cash flow from -$56.88 million in 2023 to -$86.54 million in 2024, indicating a decline in cash generation capabilities. The operating cash flow to net income ratio is negative, suggesting challenges in converting income into cash. Free cash flow to net income is also negative, highlighting cash flow difficulties despite positive net income in 2024. The high variability in cash flows suggests potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	147.56M	138.10M	101.21M	53.16M	69.57M	100.36M
Gross Profit	147.56M	138.10M	101.21M	47.31M	63.73M	100.36M
EBITDA	37.65M	26.76M	-4.31M	-98.89M	-113.34M	-77.97M
Net Income	41.60M	31.87M	-569.00K	-97.30M	-80.65M	-32.88M
Balance Sheet
Total Assets	98.50M	120.53M	201.79M	260.89M	339.41M	358.66M
Cash, Cash Equivalents and Short-Term Investments	79.89M	100.62M	174.51M	193.65M	305.23M	316.12M
Total Debt	8.15M	9.38M	13.97M	18.06M	18.06M	24.87M
Total Liabilities	73.45M	120.99M	249.24M	346.64M	250.03M	308.86M
Stockholders Equity	25.05M	-456.00K	-47.45M	-85.75M	89.38M	49.80M
Cash Flow
Free Cash Flow	-81.54M	-86.54M	-56.88M	-112.53M	-120.64M	2.95M
Operating Cash Flow	-81.23M	-86.23M	-56.03M	-110.79M	-119.03M	5.26M
Investing Cash Flow	85.41M	99.70M	-150.67M	98.26M	22.49M	-18.72M
Financing Cash Flow	7.35M	7.52M	30.23M	648.00K	110.21M	16.89M

CytomX Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Positive. The current price of 2.39 is above the 20-day moving average (MA) of 2.37, above the 50-day MA of 2.18, and above the 200-day MA of 1.22, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.66 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTMX.

CytomX Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$381.26M	4.82	-58.97%	―	23.81%	146.45%
CUE	51 Neutral	$57.72M	―	-221.66%	―	13.83%	37.66%
PDSB	50 Neutral	$56.68M	―	-119.22%	―	―	25.51%
Sector *	50 Neutral	AU$2.48B	3.17	-57.47%	2.71%	36.73%	13.67%
ARTV	44 Neutral	$49.70M	―	-68.14%	―	―	―
GUTS	43 Neutral	$74.44M	―	-196.81%	―	―	―
ACRV	36 Underperform	$41.39M	―	-62.41%	―	―	10.84%

CytomX Therapeutics Corporate Events

CytomX Therapeutics Approves Key Amendments at Annual Meeting

On June 11, 2025, CytomX Therapeutics held its Annual Meeting of Stockholders, where key amendments to the company’s equity and stock purchase plans were approved. The amendments included increasing the number of shares available under the 2015 Equity Incentive Plan, removing the evergreen provision, and extending the Employee Stock Purchase Plan indefinitely. Additionally, stockholders elected new directors, ratified the selection of Ernst & Young LLP as the independent auditor, and approved executive compensation.

The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.

CytomX Regains Nasdaq Compliance, Stabilizes Market Position

CytomX Therapeutics announced that it has regained compliance with the Nasdaq’s Minimum Bid Price Requirement after its stock price closed at $1.00 or greater for 10 consecutive trading days as of May 23, 2025. This resolution of the compliance issue stabilizes the company’s market position and avoids potential delisting, which is crucial for maintaining investor confidence and operational stability.

The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.

CytomX Therapeutics Secures $93.4 Million Through Stock Sale

On May 12, 2025, CytomX Therapeutics entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. for the sale of 76,923,076 shares of common stock at $1.30 per share, resulting in estimated net proceeds of $93.4 million. The funds are intended for research and development, general corporate purposes, and working capital needs, potentially strengthening CytomX’s position in the biotechnology sector.

The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.

CytomX Therapeutics Reports Positive Interim Phase 1 Data

On May 12, 2025, CytomX Therapeutics announced positive interim Phase 1 data for its EpCAM PROBODY® ADC candidate, CX-2051, in advanced colorectal cancer. The data, as of April 7, 2025, showed a 28% overall response rate among efficacy-evaluable patients, with a 94% disease control rate and manageable adverse events. The company has commenced dose expansions and plans to initiate a Phase 2 study in the first half of 2026. CytomX ended the first quarter with $79.9 million in cash, extending its operational runway into the second quarter of 2026, and achieved a $5 million milestone payment from Astellas.